DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Every site update, data refresh, methodology change, and editorial decision tracked publicly. 20 entries published.
The compounded-GLP-1 tracker said the FDA comment period closed June 30, 2026 (it was extended to July 30) and that the proposed 503B rule would bar bulk compounding “even in a future shortage” (the law keeps a separate shortage pathway). It also listed liraglutide as unavailable for 503B compounding — liraglutide injection is on the FDA shortage list right now, so it is permitted. New timeline entries cover FDA’s 2026 warning letters and the August 2026 appeals-court rulings. Separately, pages comparing GLP-1 pills set the Wegovy pill’s all-patients result (13.6%) against Foundayo’s stayed-on-treatment result (12.4%); on the same measure Foundayo is 11.1%.
The most important corrections: semaglutide raises levothyroxine exposure (by 33%, per the FDA label) — an earlier answer said the opposite and suggested raising the dose; pre-surgery guidance now follows the 2024 multi-society recommendation that most patients continue their GLP-1; a claim that generic semaglutide is sold in Mexico was removed (none is approved there, and the claim could steer readers to counterfeit product); an invented lipedema study was replaced with the real five-patient case series; side-effect rates on comparison and drug pages now match the FDA labels. Figures we could not trace to a source were removed rather than kept.
Earlier versions of the index included price points that no manufacturer program ever charged: “direct” prices for Wegovy and Ozempic from before NovoCare sold them, a Mounjaro self-pay series, and a compounded-telehealth series. Every price change in the index now links to the manufacturer announcement that set it. If you cited the old index, please update the figures.
Six items in our news feed described events that did not happen — among them a “May 2026” end to the Wegovy shortage (the FDA resolved it on February 21, 2025), a CMS final rule on Medicaid coverage, and a four-year SELECT follow-up paper. Three more had wrong dates, doses or prices. The feed now carries only events that link to their primary source.
Ozempic self-pay was listed at $499 (it has been $349 for the 0.25–1 mg doses since November 17, 2025); Zepbound’s list price at $1,349 (it is about $1,087); Mounjaro at $1,025 list and $549 through LillyDirect (it is about $1,112 list, with cash-pay from $499 via TrumpRx). A weekly check now compares our prices with the manufacturers’ own pages.
Insurance-appeal overturn rates (now KFF data), reflux and nausea rates (now FDA-label figures), the Wegovy MASH approval date (August 15, 2025, not March 2026), a claim that ESSENCE covered F1 fibrosis (it enrolled F2–F3 only), bariatric-regain and PCOS figures, and the FDA’s count of adverse-event reports for compounded GLP-1s.
Four page templates stamped the build date into their structured data as the “last reviewed” date, which asserted a review that had not happened. Pages now carry a review date only when the content was actually re-checked.
These pages showed the current date as their last-updated date on every visit, whether or not anything on them had changed. The stamps were removed; pages driven by live data show when that data last changed.
An audit found patient testimonials and review scores we could not trace to any source, three claims that regulators had taken action against named telehealth companies (none could be verified), trial results attributed to the wrong studies in FAQ answers, citations that linked to publisher homepages instead of papers, and an FDA warning-letter feed with invented entries. All were removed or replaced with sourced figures, and our data types now require a source link for any regulatory action.
A homepage strip suggested that major news outlets had cited our research. They had not. It was replaced with a list of the primary sources we actually cite — FDA labels, NEJM, JAMA, The Lancet, Cochrane and ClinicalTrials.gov.
Earlier versions of the site credited reviews to named, board-certified clinicians, in bylines and in structured data. They were not real people. Every such byline and credential was removed; we now describe what we actually do — check claims against FDA labels and peer-reviewed trials. Some bylines reappeared through a data re-import and were removed again on June 14, 2026.
Listen to any review or Q&A via Web Speech API ("Listen" button). New high-contrast mode toggle in header — WCAG AAA push with 3px focus rings + stronger borders. Image lightbox component shipped for product imagery.
6-step eligibility quiz matches your profile (BMI, conditions, insurance, goals) to FDA-indicated GLP-1s with prior auth likelihood. Interactive cost calculator with drug × channel × insurance carrier × duration inputs + live monthly/annual cost.
Cmd-K / Ctrl-K opens search palette across all 100+ pages (reviews, Q&A, stories, cost guides, coverage matrix). Hover any internal link to see a mini-preview card. Voice search input via Web Speech API.
Each editorial Q&A is its own URL — "Can I switch from Ozempic to Mounjaro?", "Does Medicare cover Wegovy?", "How long do Wegovy side effects last?", etc. QAPage schema markup and cited research.
Standalone "How much does X cost?" articles for 5 drugs (Wegovy/Zepbound/Ozempic/Mounjaro/Hims). Includes manufacturer direct pricing, savings programs, Medicare/Medicaid pathways, cheaper alternatives.
Our editorial methodology now publishes the literal scoring weights per page template. Best-for-condition pages weight Effectiveness 0.35; Best-in-location pages weight Accessibility 0.30. Constants pulled from src/lib/ranking.ts.
New pages for Medicaid coverage by state, cost by state, and audience-specific guides (veterans, seniors, postpartum, teens 12-17).
Drug shortage data refreshes daily from FDA Drug Shortages Database. Live badge on page indicates last-sync time. All compounded semaglutide listings now flagged with regulatory wind-down warning.
Sticky table of contents now respects prefers-reduced-motion, includes skip-to-content support, and shows reading time per section.
We publish corrections publicly. Email [email protected] with any errors or omissions. Corrections are listed on our corrections page.